Literature DB >> 11463665

Drugs for Alzheimer's disease.

J T O'Brien, C G Ballard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11463665      PMCID： PMC1120769          DOI： 10.1136/bmj.323.7305.123

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Anti-dementia drugs.

Authors:  H Allen
Journal:  Int J Geriatr Psychiatry       Date:  1999-04       Impact factor: 3.485

2.  Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

Authors: 
Journal:  Psychol Med       Date:  1998-03       Impact factor: 7.723

3.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Authors:  S L Rogers; M R Farlow; R S Doody; R Mohs; L T Friedhoff
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

4.  Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

Authors:  M A Raskind; E R Peskind; T Wessel; W Yuan
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

5.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

6.  Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

Authors:  H P Matthews; J Korbey; D G Wilkinson; J Rowden
Journal:  Int J Geriatr Psychiatry       Date:  2000-08       Impact factor: 3.485

7.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors:  M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal:  BMJ       Date:  1999-03-06

8.  The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group.

Authors:  A Hofman; W A Rocca; C Brayne; M M Breteler; M Clarke; B Cooper; J R Copeland; J F Dartigues; A da Silva Droux; O Hagnell
Journal:  Int J Epidemiol       Date:  1991-09       Impact factor: 7.196

9.  First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.

Authors:  P J Whitehouse; B Winblad; D Shostak; A Bhattacharjya; M Brod; H Brodaty; A Dor; H Feldman; F Forette; S Gauthier; J Hay; C Henke; S Hill; V Mastey; P Neumann; B O'Brien; K Pugner; M Sano; T Sawada; R Stone; A Wimo
Journal:  Alzheimer Dis Assoc Disord       Date:  1998-12       Impact factor: 2.703

10.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

Authors:  E K Perry; B E Tomlinson; G Blessed; K Bergmann; P H Gibson; R H Perry
Journal:  Br Med J       Date:  1978-11-25
  10 in total
  8 in total

1.  Drugs for Alzheimer's disease. More effective agents are needed.

Authors:  J Warner; R Butler
Journal:  BMJ       Date:  2001-11-10

Review 2.  Role of cholinesterase inhibitors in dementia care needs rethinking.

Authors:  Anthony J Pelosi; Seamus V McNulty; Graham A Jackson
Journal:  BMJ       Date:  2006-09-02

Review 3.  The safety and tolerability of donepezil in patients with Alzheimer's disease.

Authors:  Stephen Jackson; Richard J Ham; David Wilkinson
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

4.  Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia.

Authors:  P M Kemp; C Holmes; S M A Hoffmann; L Bolt; R Holmes; J Rowden; J S Fleming
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

Review 5.  Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants.

Authors:  Muhammad Ayaz; Abdul Sadiq; Muhammad Junaid; Farhat Ullah; Fazal Subhan; Jawad Ahmed
Journal:  Front Aging Neurosci       Date:  2017-05-30       Impact factor: 5.750

6.  Kinetic and toxicological effects of synthesized palladium(II) complex on snake venom (Bungarus sindanus) acetylcholinesterase.

Authors:  Mushtaq Ahmed; Shahan Zeb Khan; Naila Sher; Zia Ur Rehman; Nadia Mushtaq; Rahmat Ali Khan
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2021-04-09

7.  Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.

Authors:  Roberta Annicchiarico; Alessia Federici; Carla Pettenati; Carlo Caltagirone
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

8.  Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model.

Authors:  Faez Saleh Al-Hamed; Ola M Maria; Jeff Phan; Ahmed Al Subaie; Qiman Gao; Alaa Mansour; Lina Abu Nada; Imane Boukhatem; Osama A Elkashty; Simon D Tran; Marie Lordkipanidzé; Zahi Badran; Faleh Tamimi
Journal:  Biomolecules       Date:  2020-09-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.